Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
A bivalent factor H binding protein (fHBP) vaccine for the prevention of disease caused by Neisseria meningitidis serogroup B is currently in clinical development. Since fHBP is also expressed by other meningococcal serogroups, anti-fHBP antibodies may have bactericidal activity against meningococci independent of serogroup. To begin examining the susceptibility of other meningococcal serogroups to anti-fHBP antibodies, meningococcal serogroup C invasive isolates (n = 116) were collected from the Centers for Disease Control and Prevention's Active Bacterial Core surveillance (ABCs) sites during 2000-2001. These isolates were analyzed for the presence of the fhbp gene. All serogroup C isolates contained the gene, and sequence analysis grouped the proteins into two subfamilies, A and B. Flow cytometry analysis demonstrated that fHBP was expressed on the surface of ~70% of isolates in vitro with varying levels of expression. fHBP was accessible to antibodies on the cell surface even in the presence of the polysaccharide capsule. Nine isolates from different geographic regions were identified which harboured an identical single nucleotide deletion that could result in a truncated subfamily B fHBP. Analysis by flow cytometry using a polyclonal fHBP antibody preparation revealed that a subpopulation of each of these isolates expressed fHBP. Rabbit and non-human primate immune sera generated with bivalent fHBP vaccine were tested for bactericidal activity against a panel of diverse serogroup C clinical isolates using human complement. Sera from both species demonstrated serum bactericidal antibody activity against the serogroup C isolates tested. These promising findings suggest that a bivalent fHBP vaccine may be capable of providing protection against meningococcal disease caused by both serogroup C and B.
Pfizer Vaccine Research, Pearl River, NY, USA.
Shannon L
SL
Harris
Duzhang
D
Zhu
Ellen
E
Murphy
Lisa K
LK
McNeil
Xin
X
Wang
Leonard W
LW
Mayer
Lee H
LH
Harrison
Kathrin U
KU
Jansen
Annaliesa S
AS
Anderson
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D001426:Bacterial Proteins / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D001483:Base Sequence; D001770:Blood Bactericidal Activity; D016000:Cluster Analysis; D003165:Complement System Proteins / Q000276:immunology; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D005838:Genotype; D006801:Humans; D008252:Macaca fascicularis; D008297:Male; D008565:Membrane Proteins / Q000032:analysis / Q000235:genetics / Q000276:immunology; D008589:Meningococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D038542:Neisseria meningitidis, Serogroup C / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D011817:Rabbits; D017422:Sequence Analysis, DNA
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D008565:Membrane Proteins; D022401:Meningococcal Vaccines; C484699:factor H-binding protein, Neisseria meningitidis; D003165:Complement System Proteins
J Biol Chem. 2009 Mar 27;284(13):8738-46
19103601
Infect Immun. 2004 Apr;72(4):2088-100
15039331
J Infect Dis. 2009 Aug 1;200(3):379-89
19534597
Microbiology (Reading). 2009 Dec;155(Pt 12):4155-4169
19729409
J Immunol Methods. 2004 Sep;292(1-2):187-93
15350523
Vaccine. 2010 Aug 23;28(37):6086-93
20619376
Vaccine. 2011 Jun 24;29(29-30):4739-44
21571026
J Exp Med. 2003 Mar 17;197(6):789-99
12642606
Clin Infect Dis. 2010 Jan 15;50(2):184-91
20001736
J Infect Dis. 1995 Jun;171(6):1481-90
7769282
J Infect Dis. 2009 May 1;199(9):1360-8
19302008
Vaccine. 2009 May 26;27(25-26):3417-21
19200847